GETINGE Debt to Equity Ratio 2016-2026 | GNGBY
Current and historical debt to equity ratio values for GETINGE (GNGBY) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. GETINGE debt/equity for the three months ending June 30, 2026 was 0.26.
| GETINGE Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2026-06-30 | $2.82B | $3.31B | 0.85 |
| 2026-03-31 | $2.95B | $3.40B | 0.87 |
| 2025-12-31 | $2.76B | $3.01B | 0.92 |
| 2025-09-30 | $2.88B | $3.09B | 0.93 |
| 2025-06-30 | $2.83B | $3.00B | 0.94 |
| 2025-03-31 | $2.77B | $2.88B | 0.96 |
| 2024-12-31 | $2.91B | $3.14B | 0.93 |
| 2024-09-30 | $2.80B | $2.93B | 0.96 |
| 2024-06-30 | $2.26B | $3.04B | 0.74 |
| 2024-03-31 | $2.28B | $3.13B | 0.73 |
| 2023-12-31 | $2.19B | $2.87B | 0.76 |
| 2023-09-30 | $1.99B | $2.96B | 0.67 |
| 2023-06-30 | $2.05B | $2.97B | 0.69 |
| 2023-03-31 | $1.91B | $2.97B | 0.64 |
| 2022-12-31 | $2.14B | $3.02B | 0.71 |
| 2022-09-30 | $1.99B | $2.93B | 0.68 |
| 2022-06-30 | $2.05B | $2.87B | 0.72 |
| 2022-03-31 | $2.03B | $2.84B | 0.71 |
| 2021-12-31 | $2.26B | $2.94B | 0.77 |
| 2021-09-30 | $2.24B | $2.78B | 0.81 |
| 2021-06-30 | $2.25B | $2.71B | 0.83 |
| 2021-03-31 | $2.58B | $2.76B | 0.93 |
| 2020-12-31 | $2.57B | $2.34B | 1.10 |
| 2020-09-30 | $2.96B | $2.48B | 1.19 |
| 2020-06-30 | $2.90B | $2.20B | 1.32 |
| 2020-03-31 | $2.64B | $2.36B | 1.12 |
| 2019-12-31 | $2.51B | $2.22B | 1.13 |
| 2019-09-30 | $2.68B | $2.18B | 1.23 |
| 2019-06-30 | $2.66B | $2.12B | 1.25 |
| 2019-03-31 | $2.68B | $2.21B | 1.22 |
| 2018-12-31 | $2.73B | $2.26B | 1.21 |
| 2018-09-30 | $2.65B | $2.11B | 1.26 |
| 2018-06-30 | $2.63B | $2.39B | 1.10 |
| 2018-03-31 | $2.71B | $2.48B | 1.10 |
| 2017-12-31 | $2.62B | $2.32B | 1.13 |
| 2017-09-30 | $3.43B | $2.92B | 1.18 |
| 2017-06-30 | $3.72B | $2.28B | 1.63 |
| 2017-03-31 | $3.83B | $2.32B | 1.66 |
| 2016-12-31 | $4.01B | $2.45B | 1.64 |
| 2016-09-30 | $4.11B | $2.26B | 1.82 |
| 2016-06-30 | $4.21B | $2.31B | 1.82 |
| 2016-03-31 | $3.94B | $2.26B | 1.74 |
| 2015-12-31 | $3.99B | $2.32B | 1.72 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $6.654B | $3.574B |
| Getinge AB develops, manufactures and sells products and services for operating rooms, intensive-care units, hospital wards, sterilization departments, elderly care for life science companies and institutions. The company's operating segments consists of Medical Systems, Extended Care and Infection Control. It operates primarily in the United Kingdom, France, the United States and Australia. Getinge AB is headquartered in Gothenburg, Sweden. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $147.177B | 25.78 |
| CVS Health (CVS) | United States | $120.850B | 12.05 |
| HCA Healthcare (HCA) | United States | $91.758B | 14.27 |
| Elevance Health (ELV) | United States | $90.552B | 14.21 |
| Cencora (COR) | United States | $61.693B | 18.85 |
| Natera (NTRA) | United States | $50.563B | 0.00 |
| Labcorp Holdings (LH) | United States | $26.274B | 18.52 |
| Viatris (VTRS) | United States | $19.124B | 6.61 |
| Medpace Holdings (MEDP) | United States | $17.319B | 36.37 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $16.369B | 0.00 |
| DiDi Global (DIDIY) | China | $16.046B | 176.00 |
| Revvity (RVTY) | United States | $15.643B | 26.20 |
| Solventum (SOLV) | United States | $15.330B | 12.69 |
| ICON (ICLR) | Ireland | $13.204B | 17.94 |
| Charles River Laboratories (CRL) | United States | $13.027B | 27.56 |
| BrightSpring Health Services (BTSG) | United States | $11.642B | 40.03 |
| Avantor (AVTR) | United States | $10.443B | 18.83 |
| BioMerieux (BMXMF) | France | $10.192B | 0.00 |
| Caris Life Sciences,�Inc (CAI) | United States | $8.054B | 79.17 |
| HealthEquity (HQY) | United States | $7.983B | 26.01 |
| Sonic Healthcare (SKHHY) | Australia | $6.771B | 0.00 |
| PACS (PACS) | United States | $6.662B | 22.39 |
| CochLear (CHEOY) | Australia | $6.327B | 0.00 |
| MiniMed (MMED) | United States | $6.193B | 0.00 |
| Bausch + Lomb (BLCO) | Canada | $6.157B | 23.28 |
| Sotera Health (SHC) | United States | $5.416B | 22.33 |
| Concentras Parent (CON) | United States | $4.542B | 22.40 |
| Organon (OGN) | United States | $3.587B | 4.55 |
| GeneDx Holdings (WGS) | United States | $2.822B | 262.89 |
| CareDx (CDNA) | United States | $2.723B | 309.65 |
| Amplifon S.p.A (AMFPF) | Italy | $2.466B | 12.74 |
| Pediatrix Medical (MD) | United States | $2.169B | 12.71 |
| Alignment Healthcare (ALHC) | United States | $2.151B | 54.58 |
| Establishment Labs Holdings (ESTA) | United States | $2.130B | 0.00 |
| Progyny (PGNY) | United States | $2.130B | 30.17 |
| COMPASS Pathways (CMPS) | United Kingdom | $1.912B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $1.907B | 0.00 |
| Surgery Partners (SGRY) | United States | $1.787B | 68.25 |
| Bora Pharmaceuticals, - (BORAY) | Taiwan | $1.695B | 10.18 |
| Freenome (FRNM) | United States | $1.573B | 0.00 |
| Agilon Health (AGL) | United States | $1.547B | 0.00 |
| Ardent Health (ARDT) | United States | $1.508B | 8.62 |
| InnovAge Holding (INNV) | United States | $1.490B | 0.00 |
| Nutex Health (NUTX) | United States | $1.475B | 8.45 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.241B | 0.00 |
| Omada Health (OMDA) | United States | $1.204B | 245.88 |
| GoodRx Holdings (GDRX) | United States | $1.196B | 23.27 |
| Teladoc Health (TDOC) | United States | $1.195B | 0.00 |
| CryoPort (CYRX) | United States | $0.826B | 0.00 |
| Enhabit (EHAB) | United States | $0.709B | 25.89 |
| GMR Solutions (GMRS) | United States | $0.688B | 0.00 |
| Oncology Institute (TOI) | United States | $0.507B | 0.00 |
| Charming Medical (MCTA) | Hong Kong, SAR China | $0.504B | 0.00 |
| SBC Medicals (SBC) | United States | $0.472B | 9.77 |
| Strata Critical Medical (SRTA) | United States | $0.468B | 0.00 |
| Forward Industries (FWDI) | United States | $0.449B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.382B | 5.55 |
| Shoulder Innovations (SI) | United States | $0.374B | 0.00 |
| Biodesix (BDSX) | United States | $0.292B | 0.00 |
| Embecta (EMBC) | United States | $0.288B | 2.50 |
| So-Young (SY) | China | $0.276B | 0.00 |
| LifeMD (LFMD) | United States | $0.164B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.107B | 0.00 |
| Park Dental Partners (PARK) | United States | $0.098B | 0.00 |
| SkinHealth Systems (SKIN) | United States | $0.088B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.079B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.068B | 8.06 |
| Tevogen (TVGN) | United States | $0.050B | 0.00 |
| DocGo (DCGO) | United States | $0.038B | 0.00 |
| Lifeward (LFWD) | United States | $0.020B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.013B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.013B | 0.00 |
| Ainos (AIMD) | United States | $0.010B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.008B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.008B | 0.00 |
| XWELL (XWEL) | United States | $0.008B | 0.00 |
| Aclarion (ACON) | United States | $0.008B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.007B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.006B | 0.00 |
| 20/20 Biolabs (AIDX) | United States | $0.006B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.006B | 0.00 |
| Pomdoctor - (POM) | China | $0.006B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.004B | 0.00 | |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| INVO Fertility (IVF) | United States | $0.002B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.002B | 0.00 |
| Synergy CHC (SNYR) | United States | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |